-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Initiates Coverage On Enliven Therapeutics with Buy Rating, Announces Price Target of $60

Benzinga·06/09/2026 09:21:23
Listen to the news
Stifel analyst Dara Azar initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Buy rating and announces Price Target of $60.